Table 1.
Treatment Group | Number of Tsc2+/− Mice | Number of Males | Number of Females | Treatment Start Age (Months) | Treatment End Age (Months) | Dosage⁎ | Number of Animals Killed Due to Loss of Body Weight Within the First Month of Treatment† |
---|---|---|---|---|---|---|---|
Vehicle | 17 | 8 | 9 | 12 | 14 | 10 μl/g | 0 |
3-BrPA | 19 | 9 | 10 | 12 | 14 | 3 mg/kg | 3 |
CB-839 | 20 | 9 | 11 | 12 | 14 | 200 mg/kg | 0 |
Rapamycin | 20 | 8 | 12 | 12 | 14 | 4 mg/kg | 0 |
3-BrPA+rapamycin | 18 | 8 | 10 | 12 | 14 | 3 mg/kg+ 4 mg/kg | 3 |
CB-839+rapamycin | 20 | 8 | 12 | 12 | 14 | 200 mg/kg+ 4 mg/kg | 0 |
3-BrPA+CB-839 | 18 | 8 | 10 | 12 | 14 | 3 mg/kg+ 200 mg/kg | 4 |
Tsc2+/− mice were treated twice daily with vehicle or CB-839 via gavage and five times a week with 3-BrPA or rapamycin via intraperitoneal injection.
These mice were killed due to significant loss of body weight within the first month of treatment.